cannabidiol and Nephritis--Interstitial

cannabidiol has been researched along with Nephritis--Interstitial* in 1 studies

Other Studies

1 other study(ies) available for cannabidiol and Nephritis--Interstitial

Article	Year
Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2019, Volume: 19, Issue:10 Cannabidiol (CBD), a major purified nonpsychoactive component of cannabis with anticonvulsant properties, was approved by the U.S. Food and Drug Administration (FDA) in June 2018 as an adjuvant treatment for refractory epilepsy (Epidiolex; GW Pharmaceuticals). CBD is metabolized by cytochrome P450 (CYP)3A4 and CYP2C19 with a growing body of evidence suggesting it is also a potent inhibitor of these pathways. We report for the first time a significant drug-drug interaction between the purified CBD product and tacrolimus. A participant in a CBD clinical trial for epilepsy who was also receiving tacrolimus showed an approximately 3-fold increase in dose-normalized tacrolimus concentrations while receiving 2000-2900 mg/day of CBD. Our report delineates an important concern for the transplant community with the increasing legalization of cannabis and advent of an FDA-approved CBD product. Larger studies are needed to better understand the impact of this drug-drug interaction in solid organ transplant recipients. Topics: Adult; Cannabidiol; Drug Interactions; Epilepsy; Female; Humans; Immunosuppressive Agents; Nephritis, Interstitial; Prognosis; Tacrolimus	2019

Article

Year

Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2019, Volume: 19, Issue:10

Cannabidiol (CBD), a major purified nonpsychoactive component of cannabis with anticonvulsant properties, was approved by the U.S. Food and Drug Administration (FDA) in June 2018 as an adjuvant treatment for refractory epilepsy (Epidiolex; GW Pharmaceuticals). CBD is metabolized by cytochrome P450 (CYP)3A4 and CYP2C19 with a growing body of evidence suggesting it is also a potent inhibitor of these pathways. We report for the first time a significant drug-drug interaction between the purified CBD product and tacrolimus. A participant in a CBD clinical trial for epilepsy who was also receiving tacrolimus showed an approximately 3-fold increase in dose-normalized tacrolimus concentrations while receiving 2000-2900 mg/day of CBD. Our report delineates an important concern for the transplant community with the increasing legalization of cannabis and advent of an FDA-approved CBD product. Larger studies are needed to better understand the impact of this drug-drug interaction in solid organ transplant recipients.

Topics: Adult; Cannabidiol; Drug Interactions; Epilepsy; Female; Humans; Immunosuppressive Agents; Nephritis, Interstitial; Prognosis; Tacrolimus

2019